ASCO 2024 | Safety findings and future development of targeted alpha particle therapy in prostate cancer

Michael Morris • 3 Jun 2024

ASCO 2024

Michael Morris, MD, Memorial Sloan Kettering Cancer Center, New York, NY, examines the safety findings of targeted alpha particle therapy in prostate cancer, highlighting the importance of radiation exposure thresholds and the potential for interstitial lung disease. The discussion includes off-target effects and strategies to mitigate risks while maximizing therapeutic benefits. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Stock and Other Ownership Interests – Doximity
Consulting or Advisory Role – Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding – Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses – Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
Other Relationship – Novartis